Efficacy and Safety of Nonantibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study) A Multicentre, Randomised, Open-label, Noninferiority Trial

被引:36
|
作者
Mora-Lopez, Laura [1 ]
Ruiz-Edo, Neus [1 ]
Estrada-Ferrer, Oscar [2 ]
Luisa Pinana-Campon, Maria [3 ]
Labro-Ciurans, Meritxell [4 ]
Escuder-Perez, Jordi [5 ]
Sales-Mallafre, Ricard [6 ]
Rebasa-Cladera, Pere [1 ]
Navarro-Soto, Salvador [1 ]
Serra-Aracil, Xavier [1 ]
机构
[1] Univ Autonoma Barcelona, Coloproctol Unit, Parc Tauli Univ Hosp,Dept Surg, Sabadell,Inst Invest & Innovacio,Parc Tauli I3PT, Barcelona, Spain
[2] Mataro Hosp, Coloproctol Unit, Mataro, Spain
[3] Hosp Univ St Joan Reus, Dept Surg, Reus, Spain
[4] Hosp St Joan de Deu Manresa, Dept Surg, Manresa, Spain
[5] Joan XXIII Univ Hosp, Coloproctol Unit, Tarragona, Spain
[6] Hosp St Pau & Santa Tecla, Santa Tecla, El Salvador
关键词
mild acute diverticulitis; nonantibiotic in acute diverticulitis; outpatient in acute diverticulitis; MODIFIED NEFF CLASSIFICATION; CLINICAL-TRIAL; ANTIBIOTICS; MANAGEMENT;
D O I
10.1097/SLA.0000000000005031
中图分类号
R61 [外科手术学];
学科分类号
摘要
Objective: Mild AD can be treated safely and effectively on an outpatient basis without antibiotics. Summary of Background Data: In recent years, it has shown no benefit of antibiotics in the treatment of uncomplicated AD in hospitalized patients. Also, outpatient treatment of uncomplicated AD has been shown to be safe and effective. Methods: A Prospective, multicentre, open-label, noninferiority, randomized controlled trial, in 15 hospitals of patients consulting the emergency department with symptoms compatible with AD. The Participants were patients with mild AD diagnosed by Computed Tomography meeting the inclusion criteria were randomly assigned to control arm (ATB-Group): classical treatment (875/125 mg/8 h amoxicillin/clavulanic acid apart from anti-inflammatory and symptomatic treatment) or experimental arm (Non-ATB-Group): experimental treatment (antiinflammatory and symptomatic treatment). Clinical controls were performed at 2, 7, 30, and 90 days. The primary endpoint was hospital admission. Secondary endpoints included number of emergency department revisits, pain control and emergency surgery in the different arms. Results: Four hundred and eighty patients meeting the inclusion criteria were randomly assigned to Non-ATB-Group (n = 242) or ATB-Group (n = 238). Hospitalization rates were: ATB-Group 14/238 (5.8%) and Non-ATB-Group 8/242 (3.3%) [mean difference 2.58%, 95% confidence interval (CI) 6.32 to -1.17], confirming noninferiority margin. Revisits: ATB-Group 16/238 (6.7%) and Non-ATB-Group 17/242 (7%) (mean difference -0.3, 95% CI 4.22 to -4.83). Poor pain control at 2 days follow up: ATB-Group 13/230 (5.7%), Non-ATB-Group 5/221 (2.3%) (mean difference 3.39, 95% CI 6.96 to -0.18). Conclusions: Nonantibiotic outpatient treatment of mild AD is safe and effective and is not inferior to current standard treatment.
引用
收藏
页码:E435 / E442
页数:8
相关论文
共 50 条
  • [32] An Open-label Study of the Safety and Efficacy of Sertaconazole Nitrate in the Treatment of Seborrheic Dermatitis
    Elewski, Boni E.
    Cantrell, Wendy C.
    JOURNAL OF DRUGS IN DERMATOLOGY, 2011, 10 (08) : 895 - 899
  • [33] Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial
    Mazighi, Mikael
    Richard, Sebastien
    Lapergue, Bertrand
    Sibon, Igor
    Gory, Benjamin
    Berge, Jerome
    Consoli, Arturo
    Labreuche, Julien
    Olivot, Jean-Marc
    Broderick, Joseph
    Duhamel, Alain
    Touze, Emmanuel
    Qureshi, Adnan, I
    Yavchitz, Amelie
    Escalard, Simon
    Desilles, Jean-Philippe
    Redjem, Hocine
    Smajda, Stanislas
    Fahed, Robert
    Hebert, Solene
    Maier, Benjamin
    Delvoye, Francois
    Boursin, Perrine
    Maacha, Malek Ben
    Obadia, Michael
    Sabben, Candice
    Blanc, Raphael
    Savatovsky, Julien
    Piotin, Michel
    LANCET NEUROLOGY, 2021, 20 (04): : 265 - 274
  • [34] The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial
    van Zijverden, Lieve Mees
    Schutte, Moya Henriette
    Madsen, Milou Cecilia
    Bonten, Tobias Nicolaas
    Smulders, Yvo Michiel
    Wiepjes, Chantal Maria
    van Diemen, Jeske Joanna Katarina
    Thijs, Abel
    CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (07) : 3501 - 3508
  • [35] The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial
    Lieve Mees van Zijverden
    Moya Henriëtte Schutte
    Milou Cecilia Madsen
    Tobias Nicolaas Bonten
    Yvo Michiel Smulders
    Chantal Maria Wiepjes
    Jeske Joanna Katarina van Diemen
    Abel Thijs
    Clinical and Experimental Medicine, 2023, 23 : 3501 - 3508
  • [36] Analgesic Efficacy, Practicality and Safety of Inhaled Methoxyflurane Versus Standard Analgesic Treatment for Acute Trauma Pain in the Emergency Setting: A Randomised, Open-Label, Active-Controlled, Multicentre Trial in Italy (MEDITA)
    Sebastiano Mercadante
    Antonio Voza
    Sossio Serra
    Germana Ruggiano
    Giuseppe Carpinteri
    Gianfilippo Gangitano
    Fabio Intelligente
    Elisabetta Bonafede
    Antonella Sblendido
    Alberto Farina
    Amedeo Soldi
    Andrea Fabbri
    Advances in Therapy, 2019, 36 : 3030 - 3046
  • [37] Analgesic Efficacy, Practicality and Safety of Inhaled Methoxyflurane Versus Standard Analgesic Treatment for Acute Trauma Pain in the Emergency Setting: A Randomised, Open-Label, Active-Controlled, Multicentre Trial in Italy (MEDITA)
    Mercadante, Sebastiano
    Voza, Antonio
    Serra, Sossio
    Ruggiano, Germana
    Carpinteri, Giuseppe
    Gangitano, Gianfilippo
    Intelligente, Fabio
    Bonafede, Elisabetta
    Sblendido, Antonella
    Farina, Alberto
    Soldi, Amedeo
    Fabbri, Andrea
    Rug-giano, Germana
    Tota, Guido
    Zerini, Michela
    Semino, Alessandra
    Rasla, Sara
    Mecatti, Elena
    Panci, Gabriele
    Fronduti, Catia
    Signoroni, Patrizia
    Corradini, Alessandro
    Benucci, Alessandra
    Bartoli, Isabella
    Messina, Davide
    Noto, Paola
    Giraffa, Chiara
    Bermano, Francesco
    Lapini, Cristina
    Chiesa, Maurizio
    Sabini, Beatrice
    Oppes, Mario
    Pretti, Vincenzo
    Masciari, Peppino
    Comito, Antonietta
    Orlando, Lucia
    Torti, Davide
    Carbone, Giorgio
    Alberto, Gianfrancesco
    Iorno, Vittorio
    Barraco, Alessandro
    Suardi, Monica
    Addari, Claudio
    Paolini, Piero
    Bertocci, Nicola
    Tranelli, Stefano
    Di Conza, Pasquale
    Valentino, Alessandro
    Cuppini, Patrizia
    Lucchi, Elisabetta
    ADVANCES IN THERAPY, 2019, 36 (11) : 3030 - 3046
  • [38] Tofacitinib in Pediatric Psoriasis: An Open-Label Trial to Study Its Safety and Efficacy in Children
    AlMutairi, Nawaf
    Nour, Tarek
    DERMATOLOGY, 2020, 236 (03) : 191 - 198
  • [39] Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seizures in a multicentre open-label single-arm trial in Korean patients
    Heo, Kyoung
    Lee, Byung In
    Do Yi, Sang
    Huh, Kyoon
    Kim, Jae Moon
    Lee, Sang Ahm
    Shin, Dong Jin
    Song, Hong Ki
    Lee, Sang Kun
    Kim, Jeong Yeon
    Lu, Sarah
    Dubois, Cecilia
    Tonner, Francoise
    SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2007, 16 (05): : 402 - 409
  • [40] Thoracentesis to alleviate pleural effusion in acute heart failure: study protocol for the multicentre, open-label, randomised controlled TAP-IT trial
    Glargaard, Signe
    Thomsen, Jakob Hartvig
    Logstrup, Brian Bridal
    Schou, Morten
    Iversen, Kasper Karmark
    Tuxen, Christian
    Nielsen, Olav W.
    Bang, Christian Axel
    Lindholm, Matias Greve
    Seven, Ekim
    Barasa, Anders
    Stride, Nis
    Vraa, Soren
    Tofterup, Marlene
    Rasmussen, Rasmus Vedby
    Hofsten, Dan Eik
    Rossing, Kasper
    Kober, Lars
    Gustafsson, Finn
    Thune, Jens Jakob
    BMJ OPEN, 2024, 14 (01):